NYSE:PFE - Pfizer Stock Price, Price Target & More

Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."

Pfizer announced a quarterly dividend on Thursday, June 28th. Stockholders of record on Friday, August 3rd will be given a dividend of $0.34 per share on Tuesday, September 4th. This represents a $1.36 annualized dividend and a dividend yield of 3.64%. The ex-dividend date is Thursday, August 2nd. View Pfizer's Dividend History.

Pfizer declared that its Board of Directors has authorized a share buyback program on Tuesday, December 19th 2017, which authorizes the company to repurchase $10,000,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase shares of its stock through open market purchases. Stock repurchase programs are often an indication that the company's board of directors believes its shares are undervalued.

Pfizer Inc. (NYSE:PFE) released its quarterly earnings data on Tuesday, May, 1st. The biopharmaceutical company reported $0.77 EPS for the quarter, topping the consensus estimate of $0.74 by $0.03. The biopharmaceutical company had revenue of $12.91 billion for the quarter, compared to the consensus estimate of $13.14 billion. Pfizer had a net margin of 41.29% and a return on equity of 25.29%. The business's revenue for the quarter was up 1.0% on a year-over-year basis. During the same period last year, the company posted $0.69 EPS. View Pfizer's Earnings History.

Pfizer is scheduled to release their next quarterly earnings announcement on Tuesday, July, 31st 2018. View Earnings Estimates for Pfizer.

Pfizer updated its FY18 earnings guidance on Tuesday, May, 1st. The company provided EPS guidance of $2.90-3.00 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.95. The company issued revenue guidance of $53.5-55.5 billion, compared to the consensus revenue estimate of $54.45 billion.

20 brokerages have issued 12 month price targets for Pfizer's stock. Their forecasts range from $36.00 to $45.00. On average, they anticipate Pfizer's share price to reach $40.4167 in the next twelve months. This suggests a possible upside of 8.3% from the stock's current price. View Analyst Ratings for Pfizer.

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last year. There are currently 2 sell ratings, 9 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold."

Pfizer saw a decline in short interest in June. As of June 29th, there was short interest totalling 59,174,572 shares, a decline of 8.5% from the June 15th total of 64,685,349 shares. Based on an average trading volume of 21,034,138 shares, the short-interest ratio is presently 2.8 days. Currently, 1.0% of the company's stock are sold short. View Pfizer's Current Options Chain.

Some companies that are related to Pfizer include Johnson & Johnson (JNJ), Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Sanofi (SNY), GlaxoSmithKline (GSK), Eli Lilly And Co (LLY), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Allergan (AGN) and Shire (SHPG).

Media stories about PFE stock have been trending positive on Monday, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Pfizer earned a news sentiment score of 0.35 on Accern's scale. They also assigned media coverage about the biopharmaceutical company an impact score of 45.33 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Pfizer's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Fisher Asset Management LLC (0.66%), Bank of Montreal Can (0.37%), Hexavest Inc. (0.10%), NN Investment Partners Holdings N.V. (0.09%), Swedbank (0.06%) and Retirement Systems of Alabama (0.05%). Company insiders that own Pfizer stock include Albert Bourla, Alexander R Mackenzie, Anthony J Maddaluna, Charles H Hill, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Mikael Dolsten, Rady A Johnson, Sally Susman and W Don Cornwell. View Institutional Ownership Trends for Pfizer.

PFE stock was sold by a variety of institutional investors in the last quarter, including RNC Capital Management LLC, Hexavest Inc., Bank of Montreal Can, Hartford Investment Management Co., Meag Munich Ergo Kapitalanlagegesellschaft MBH, Assenagon Asset Management S.A., Retirement Systems of Alabama and Swedbank. Company insiders that have sold Pfizer company stock in the last year include Alexander R Mackenzie, Charles H Hill, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Mikael Dolsten, Rady A Johnson, Sally Susman and W Don Cornwell. View Insider Buying and Selling for Pfizer.

PFE stock was purchased by a variety of institutional investors in the last quarter, including Jensen Investment Management Inc., Fisher Asset Management LLC, Cornerstone Wealth Management LLC, TIAA FSB, State of Alaska Department of Revenue, Pwmco LLC, Calamos Advisors LLC and IFM Investors Pty Ltd. View Insider Buying and Selling for Pfizer.

Shares of PFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PFE stock can currently be purchased for approximately $37.33.

Pfizer has a market capitalization of $222.22 billion and generates $52.55 billion in revenue each year. The biopharmaceutical company earns $21.31 billion in net income (profit) each year or $2.65 on an earnings per share basis. Pfizer employs 90,200 workers across the globe.

Pfizer's mailing address is 235 EAST 42ND STREET, NEW YORK NY, 10017. The biopharmaceutical company can be reached via phone at 212-733-2323.